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Background. Direct-acting antivirals (DAAa) cure hepatitis C virus (HCV) infections in 95% of infected patients. Modeling 
studies predict that universal HCV treatment will lead to a decrease in the incidence of new infections but real-life data are lacking. 
The incidence of HCV among Dutch human immunodeficiency virus (HIV)–positive men who have sex with men (MSM) has been 
high for >10 years. In 2015 DAAs became available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-
positive MSM. We assessed whether this uptake was followed by a decrease in the incidence of HCV infections.
Methods. Two prospective studies of treatment for acute HCV infection enrolled patients in 17 Dutch HIV centers, having 76% 
of the total HIV-positive MSM population in care in the Netherlands. Patients were recruited in 2014 and 2016, the years before and 
after unrestricted DAA availability. We compared the HCV incidence in both years.
Results. The incidence of acute HCV infection decreased from 93 infections during 8290 person-years of follow-up (PYFU) 
in 2014 (11.2/1000 PYFU; 95% confidence interval [CI], 9.1–13.7) to 49 during 8961 PYFU in 2016 (5.5/1000 PYFU; 4.1–7.2). The 
incidence rate ratio of 2016 compared with 2014 was 0.49 (95% CI, .35–.69). Simultaneously, a significant increase in the percent-
age positive syphilis (+2.2%) and gonorrhea (+2.8%) tests in HIV-positive MSM was observed at sexual health clinics across the 
Netherlands and contradicts a decrease in risk behavior as an alternative explanation.
Conclusions. Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among 
HIV-positive MSM.
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A high incidence of acute hepatitis C virus (HCV) infections 
in human immunodeficiency virus (HIV)–positive men who 
have sex with men (MSM) has been observed in many European 
countries, as well as in Australia and the United States [1–3]. 
Indeed, during anal intercourse and additional high-risk behav-
ior with increased likelihood of blood-blood contact, HCV can 
be readily transmitted from man to man [4]. This contrasts with 
the very low incidence of transmission during heterosexual con-
tacts [5]. Several recent studies described an incidence of acute 
HCV infection in Dutch HIV-positive MSM of 1.1% or 11/1000 
person-years of follow-up (PYFU) [6–8]. This is an extremely 
high incidence in a country where the overall HCV prevalence is 
estimated at 0.2% [9]. Van Santen et al [10] described a compar-
ably high incidence of acute HCV infection among HIV-positive 
MSM in several other European countries.
As of July 2014, interferon-free HCV therapy with direct-act-
ing antivirals (DAAs) became reimbursed for all Dutch inhabit-
ants with chronic HCV-induced severe liver fibrosis or cirrhosis. 
At that time, the very high costs of these drugs were the reason 
DAA therapy did not became available to all patients infected 
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with HCV. Eventually, the restriction to patients with severe 
liver disease was lifted on 1 November 2015. As a result, the 
Netherlands was one of the first European countries in which 
DAA therapy became available to all chronically HCV-infected 
patients without any restrictions.
We recently showed that the unrestricted DAA availability 
was followed by a very rapid HCV treatment uptake among 
HIV-positive MSM with chronic HCV. Indeed, 76% of the Dutch 
HIV-positive MSM ever infected with HCV were already shown 
to have their HCV infection cured as of January 2017 [11].
Mathematical modeling studies have predicted that by 
decreasing the pool of infectious persons in the population, 
the immediate treatment with DAAs of all HCV-infected HIV-
positive MSM would lead to a progressive decline in the inci-
dence of acute HCV infections [12–14]. However, this assumed 
decline in incidence has yet to be confirmed with real-life ob-
servational data. Therefore, the aim of this study was to investi-
gate whether the countrywide rollout of DAAs was followed by 
a decline in the number of acute HCV infections among HIV-
positive MSM within the Netherlands.
PATIENTS AND METHODS
According to Dutch HIV treatment guidelines, HCV infections in 
HIV-positive MSM attending the HIV outpatient clinic are diag-
nosed by means of HCV antibody testing (followed by HCV RNA 
testing when antibody test results are positive) at entry into HIV 
care. Thereafter, HCV immunoglobulin G testing is performed 
once a year, and HCV RNA testing is also done if a new alanine 
aminotransferase (ALT) elevation is observed. Liver enzyme level 
are measured during the biannual HIV viral load monitoring.
An acute HCV infection was defined as a positive HCV RNA 
test, preceded by a negative HCV test in the previous 12 months. 
Because HIV centers in the Netherlands store leftover plasma 
from each outpatient visit, retesting of superfluous plasma from 
the preceding outpatient visit was possible in the majority of the 
patients to confirm that the patient had been HCV negative in the 
previous year. However, if stored plasma was not available, a new 
HCV diagnosis was also considered to be an acute HCV infection 
if a normal ALT measurement within the last 12 months preceded 
the first positive HCV RNA test and a documented negative HCV 
test was available from any time in the past and no other possible 
explanation for the ALT elevation was found [15].
An acute HCV reinfection was defined as a positive HCV 
RNA test after a previously documented sustained virologi-
cal response 12 weeks or more after the end of HCV therapy. 
For patients treated in the Dutch Acute HCV in HIV Studies 
(DAHHS), in case HCV RNA became detectable again within 
12 weeks after the end of therapy, HCV RNA was also geno-
typed and sequenced to differentiate relapse from reinfection.
Currently there is no systematic registry in place for acute 
HCV infections in the Netherlands. We therefore used the data 
from 2 prospective studies as a proxy. The DAHHS group is a 
network of 17 hospitals that performs multicenter clinical trials 
on the treatment of acute HCV infection [16, 17]. None of the 
currently available DAAs have been registered for the treatment 
of an acute HCV infection. Therefore and to evaluate the effect-
iveness of DAAs for the treatment of acute HCV infection, the 
DAHHS1 and DAHHS2 studies were designed. Both are pro-
spective studies that evaluated (DAHHS1 in 2014) or are eval-
uating (DAHHS2 in 2016 and ongoing) different DAA-based 
options for the treatment of acute HCV infection. Because these 
studies enroll patients prospectively, they enabled us to register 
all acute HCV infections diagnosed in the DAHHS centers and 
compare the incidence of acute HCV infections among HIV-
positive MSM in the year before (2014) and in the first year after 
(2016) interferon-free DAAs became available for the treatment 
of chronic HCV infection in the Netherlands.
Patient characteristics were collected by the treating physician 
and transferred to the study coordinator after pseudonymization. 
All patients consented to have their data used for research pur-
poses in the context of the HIV AIDS Therapy Evaluation in the 
Netherlands (ATHENA) cohort [18]. Data on the number of HIV-
positive MSM and on the HCV prevalence among HIV-positive 
MSM in care across all HIV centers in the Netherlands were pro-
vided by Stichting HIV Monitoring (HIV Monitoring Foundation), 
responsible for data collection of the patients in the ATHENA 
cohort. The ATHENA cohort consists of 98% of the patients in care 
for a diagnosed HIV infection in the Netherlands [18].
The incidence of acute HCV infection in the year 2014, the 
last year before DAAs became available, and 2016, the first year 
after unrestricted DAA availability, was calculated by dividing the 
number of acute HCV infection cases by the PYFU of all HIV-
positive MSM in that year in the 17 study centers. To compare 
the acute HCV incidence in 2016 with 2014, we calculated the 
incidence rate ratio (IRR) with 95% confidence intervals (CIs).
Because HCV infections are transmitted sexually among MSM, 
national data on the incidence of the sexually transmitted dis-
eases (STDs) syphilis and gonorrhea in MSM were used as a sur-
rogate marker for the evaluation of possible trends in sexual risk 
behavior. These data are provided by the STD/HIV Surveillance 
Unit of the National Institute for Public Health and Environment, 
which collects, integrates and interprets data from multiple sur-
veillance sources in the Netherlands, including data from registra-
tion by sentinel STD clinics and HIV treatment centers [19, 20].
RESULTS
In 2014, a total of 93 acute HCV infections were diagnosed in 
the 17 study centers during 8290 PYFU (incidence, 11.2/1000 
PYFU; 95% CI, 9.1–13.7). In contrast, 49 acute HCV infec-
tions were diagnosed during 8961 PYFU in 2016 (incidence 
of 5.5/1000 PYFU; 4.1–7.2). Thus, the IRR for 2016 compared 
with 2014 was 0.49 (95% CI, .35–.69). During the first 4 months 
of 2017, the incidence was 5.6 per 1000 PYFU (17/3047 PYFU) 
and comparable to the overall incidence in 2016.
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In 2014, the majority of acute HCV infections were caused 
by HCV genotype 1 (72 of 93; 77%). The proportion of gen-
otype 1 in acute HCV infection decreased in 2016 (27 of 49; 
55%) (Figure 1). Consequently, the IRR for genotype 1 infec-
tions comparing 2016 with 2014 was 0.35 (95% CI, .22–.54). 
Looking at the smaller group of genotype 4 infections only, the 
decline was less pronounced and not statistically significant 
(IRR, 0.77; 95% CI, .54–1.09). A change in the distribution of 
the nation of origin of the patients with acute HCV infection 
of genotype 1 or 4 could not explain the difference in decline in 
the incidence of genotype 1 and 4. Indeed, 23 of 93 patients with 
an acute HCV infection diagnosed in 2014 were born outside 
the Netherlands, comparable to the proportion in 2016 (8 of 49; 
P = .29). Figure 2 illustrates the incidence of acute HCV infec-
tion for every 4 months of the calendar year and per genotype 
in 2014, 2016, and the first 4 months of 2017.
The absolute number of acute HCV infections decreased both 
in patients with a first acute HCV infection and in patients who 
had an acute HCV reinfection after a previously cured HCV 
infection, whereas the proportion of reinfections remained 
constant between 2014 and 2016 (23% [21 of 93] and 24% [12 
of 49], respectively) (P = .8) (Table 1).
In the years that preceded the introduction of DAAs, the 
proportion of HIV-positive MSM in the Netherlands who were 
HCV RNA positive (and thus a potential source for new infec-
tions) was stable, at 4.2 % in 2013 (396 of 9513) and 4.1% in 
2015 (450 of 11 070). The unrestricted access to DAAs caused a 
prompt and substantial decrease of this infectious pool to 1.5% 
(176 of 11 749) by the end of 2016 (data provided by Stichting 
HIV Monitoring; Figure 1). Comparing 2016 with 2014, there 
was a substantial increase in the percentage of positive syph-
ilis (from 6.6% [281 of  4240] to 8.4% [435 of  5185], respect-
ively; P  =  .001) and gonorrhea (from 16.4% [697 of  4239] to 
19.2% [1005 of 5228]; P < .001) tests among HIV-positive MSM 
attending sentinel STD clinics in the Netherlands [19, 20].
DISCUSSION
We observed a 51% decrease in acute HCV infections in 2016 
compared with 2014. As far as we know, ours is the first study 
using real-life data to lend support to what recent modeling 
studies have predicted: universal HCV therapy for all HIV-
positive MSM chronically infected with HCV will decrease the 
number of acute HCV infections in this population [12–14].
The decline in acute HCV infections was more pronounced 
for HCV genotype 1 (65% decrease) than for genotype 4 
(23%). Treatment of acute HCV infection in the context of the 
DAHHS1 study (only HCV genotype 1 infections could be 
treated in this study) may possibly explain the more substan-
tial decrease we observed in genotype 1 infections compared 
with genotype 4 infections. Indeed, as many as 79% of the 72 
patients with an acute HCV genotype 1 infection diagnosed in 
the 17 study centers in 2014 were treated in the DAHHS1 study, 
and 86% of them had their infection cured and therefore no 
longer a source of new genotype 1 infections [15, 16]. However, 
the chronic HCV treatment uptake among Dutch HIV-positive 
patients in general did not differ between genotype 1 and 4, 
and neither was there a difference in uptake in relation to their 
country of origin, so a disparity in HCV treatment uptake based 
on country of origin or genotype cannot explain the smaller de-
crease in the incidence of acute HCV infection of genotype 4 
compared with genotype 1. It is well known that outbreaks of 
acute HCV infection occur frequently and this may have been 
the case for genotype 4. Indeed, as illustrated in Figure 2, 80% 
of the genotype 4 infections in 2016 were diagnosed in the first 
4 months of 2016.
The incidence of HCV reinfection among HIV-positive MSM 
with a previously cured HCV infection has historically been 
very high [21]. Therefore, this subgroup of patients may be at the 
core of the HCV epidemic. In this regard, it is reassuring that we 
observed a decrease in the number of HCV reinfections as well 
(from 21 to 12), despite a substantial increase in the population 
at risk for reinfection. Indeed, as a result of the HCV treatment 
Figure 1. Hepatitis C virus (HCV) infections in human immunodeficiency virus 
(HIV)–positive men who have sex with men (MSM) in care in the Netherlands. A, 
Percentage of HIV-positive MSM in care in the Netherlands who remained HCV 
RNA positive in 2014 and 2016. B, Number of acute HCV infections in 2014 and 
2016. IRR, incidence rate ratio.
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uptake and the consequent decline of HCV RNA positive 
patients from 4.2% in 2013 to 1.5% at the end of 2016, the num-
ber of patients whose HCV infection has been cured and who 
are therefore at risk for reinfection has increased substantially.
In contrast to the decline in acute HCV infections, the num-
ber of MSM with syphilis or gonorrhea diagnosed at STD 
clinics across the Netherlands increased substantially in 2016. 
Therefore, it is very unlikely that the decline in acute HCV infec-
tions we observed is the result of reduced sexual risk behavior. In 
2015, Vanhommerig et al found [4] that in HIV-positive MSM, 
receptive unprotected anal intercourse, sharing sex toys, unpro-
tected fisting and a recent diagnosis of ulcerative STDs were all 
independent risk factors for the acquisition of acute HCV infec-
tion. Moreover, intravenous drug use (IVDU) before or during 
sex (also called slamming or “slamsex”) was another significant 
risk factor. However, only 11% (9 of 82) of the patients with an 
acute HCV infection included in their study reported IVDU as 
a risk factor. Therefore, we consider it unlikely that a decrease in 
IVDU among HIV-positive MSM in 2016 compared with 2014 
can explain our observations. Second, a recent study into Q80K 
phylogeny in Dutch HCV genotype 1a–infected patients showed 
no intermingling of HIV-positive MSM and people who inject 
drugs (PWID) [22]. Although injection drug use (whether intra-
venous or subcutaneous) during sex does occur in a small num-
ber of HIV-positive MSM [4] and sexual networks seem to be 
highly dynamic [23], it is unlikely that HCV strains from Dutch 
PWID fuel the HCV epidemic in Dutch HIV-positive MSM [22].
The strength of our study is the prospective data collection on 
the incidence of acute HCV in 17 HIV centers. These 17 centers 
are representative of the whole of the Netherlands, because they 
are located in all major Dutch cities and provide HIV therapy 
to >75% of all HIV-positive MSM in care in the Netherlands.
Our study has several limitations. First, an observational 
study cannot prove that the DAA uptake is the cause of the 
decline in the incidence of acute HCV infection. A  substan-
tial change in risk behavior may have led to a similar decrease. 
We did not measure IVDU in our cohort; however, as stated 
above, IVDU does not seem to be an important risk behavior 
in Dutch HIV-positive MSM, although this may change over 
time. Second, from modeling studies in PWID it is known that 
treatment scale-up can have a bigger impact on a stable versus 
an increasing HCV epidemic [24]. In contrast to the stable HCV 
incidence in HIV-positive MSM in the Netherlands, other parts 
of Europe still see a rising incidence of HCV infections [10], 
so treatment scale-up may not have the same effect on those 
epidemics. Therefore, our data should be extrapoloated to other 
settings with caution. 
Third, the proportion of chronically HCV-infected patients, 
who are very unlikely to have a new acute HCV superinfection 
diagnosed (because they are already HCV RNA positive) was 
not subtracted from the total PYFU of HIV-positive MSM in the 
Table 1. Baseline Characteristics of Patients With Acute Hepatitis C 
Virus Infection Diagnosed in 2014 or 2016
Characteristic
Patients With Acute HCV Infection
P Value2014 (n = 93) 2016 (n = 49)
Age, mean (SD), y 42 (9) 46 (9) .06
Receiving cART, No. (%) 84 (90) 43 (94) .53
CD4 cell count, median (IQR), 
cells/μL 
610 (430–810) 620 (465–763) .86
Reinfection, No. (%) 21 (23) 12 (25) .75
HCV genotype, No. (%)
 Genotype 1 72 (77) 27 (55) .02
 Genotype 2 2 (2) 1 (2)
 Genotype 3 0 2 (4)
 Genotype 4 18 (19) 15 (31)
 Missing 1 (1) 4 (8)
HCV genotype 1 subtype, 
No. (%)
 Subtype a 68 (73) 27 (55) .57
 Subtype b 4 (4) 0
Abbreviations: cART, combination antiretroviral therapy; HCV, hepatitis C virus; IQR, inter-
quartile range; SD, standard deviation.
Figure 2. Left axis, Acute hepatitis C virus (HCV) infections per 4 months and per genotype. Right axis, Percentage of HCV RNA–positive human immunodeficiency 
virus (HIV)–positive men who have sex with men (MSM) (blue) and number of HCV treatments (red) in the Netherlands per year (data for both obtained from Stichting HIV 
Monitoring; personal communication). T1: Jan–Apr; T2: May–Aug; T3: Sept–Dec.
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incidence calculations. However, excluding them from the IRR 
calculation would further lower the IRR from 0.49 to 0.47. Fourth, 
by the end of 2015 a certain number of MSM were living with 
HIV but were unaware of their HIV infection and therefore not 
in care. As such, our conclusions cannot be extrapolated to this 
HIV-infected MSM population. However, in the Netherlands this 
fraction has been estimated to be small, about 10% [25]. Finally, 
acute HCV infections often occur in localized outbreaks, and tem-
porary fluctuations in the incidence can be expected; longer-term 
data are therefore needed to confirm that the decrease we have 
observed is not the result of an extreme fluctuation by chance.
Although the 51% decrease of acute HCV infections we de-
scribe is encouraging, it is very unlikely that DAA therapy for 
all HCV/HIV-coinfected patients as a single intervention will 
lead to elimination of HCV among Dutch HIV-positive MSM 
[12, 13]. This prediction is also suggested by the apparent lack 
of a further decline in incidence during the first 4 months of 
2017. Other interventions are thus needed. First, the incidence 
of acute HCV infections in HIV-positive MSM is high in major 
cities of all countries neighboring the Netherlands [26, 27]. 
Owing to the continuous restrictions of DAAs to patients with 
severe liver disease in some of these countries, the DAA treat-
ment uptake there has been limited. Therefore, cross-border 
HCV transmissions will continue to occur as long as compar-
able treatment uptake does not occur in neighboring countries 
[28]. 
Second, although in the Netherlands the prevalence of HCV 
infection in HIV-negative MSM attending STD clinics [7] and 
the number of reported cases of acute HCV infection in HIV-
negative MSM has been low [29], the prevalence is probably 
substantially higher in a certain subset of MSM. Exemplary 
for this are the very recent observations in an HIV preexpo-
sure prophylaxis (PrEP) implementation project in Amsterdam. 
On entering the PrEP program 15 patients (4%) had detectable 
HCV RNA [30]. Risk compensation and an increase in the inci-
dence of STD during PrEP use may also occur and could lead to 
an increase in HCV transmission among PrEP recipients [31]. 
We therefore think that the prevalence of HCV must be moni-
tored among HIV-negative MSM engaging in unprotected anal 
intercourse, and in particular MSM receiving PrEP. 
Third, several studies have observed an extremely high acute 
HCV reinfection rate in patients with a previously cured HCV 
infection [26, 32, 33]. Therefore, a specific focus on HIV-positive 
MSM with a history of an HCV infection is needed. This may 
consist of very frequent HCV testing (eg, every 3 months) with 
the aim of diagnosing and treating HCV reinfections as early 
as possible [34]. Last but not least, counseling on sexual risk 
behavior is important, along with, when appropriate, referral to 
specialized clinics for problematic recreational drug use in the 
context of “chemsex” or slamsex [13], because not only IVDU 
but also orally administrated drugs seem to be associated with 
HCV transmission among HIV-positive MSM [4].
In conclusion, a 51% decrease in acute HCV infections was 
observed among HIV-positive MSM in 2016 compared with 
2014. An HCV “treatment as prevention” effect caused by the 
rapid DAA treatment uptake among HIV-positive MSM with 
chronic HCV is the most plausible explanation for this decline.
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